The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers

CMAJ. Canadian Medical Association Journal

Volumn 183, Issue 3, 2011, Pages 303-307

  Wright, Alissa J ^a   Gomes, Tara ^f   Mamdani, Muhammad M ^b,c,f   Horn, John R ^d   Juurlink, David N ^a,e,f  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF WASHINGTON   (United States)

^e Sunnybrook Health Sciences Centre   (Canada)

^f INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AZITHROMYCIN; CALCIUM CHANNEL BLOCKING AGENT; CLARITHROMYCIN; CYTOCHROME P450 3A4; DIHYDROPYRIDINE; DILTIAZEM; ERYTHROMYCIN; FELODIPINE; NIFEDIPINE; VERAPAMIL;

AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRESCRIPTION; RISK; SHOCK;

EID: 79951965682     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.100702     Document Type: Article

References (20)

1. IMS Health. Top therapeutic classes by dispensed prescriptions. Thetford Center (VT): MarketingCharts. Available: www.marketingcharts.com/topics/us- prescription-drug-sales-grow-slowly-hydrocodone-most-prescribed-8462/ ims-top-15-us-therapeutic-classes-dispensed-prescriptions-2008jpg/ (accessed 2009 July 1).
2. Periti P, Mazzei T, Mini E, et al. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992;23:106-31.
3. Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 2000;50:285-95.
4. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57. (Pubitemid 30055093)
5. Zhou S, Chan E, Li X, et al. Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. Ther Clin Risk Manag 2005;1:3-13.
6. Sica DA. Interaction of grapefruit juice and calcium channel blockers. Am J Hypertens 2006;19:768-73. (Pubitemid 43928515)
7. Dorne JL, Walton K, Renwick AG. Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. Food Chem Toxicol 2003;41:201-24. (Pubitemid 35447872)
8. Bailey DG, Bend JR, Arnold JM, et al. Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin Pharmacol Ther 1996;60:25-33. (Pubitemid 26279217)
9. Liedholm H, Nordin G. Erythromycin-felodipine interaction. DICP 1991;25:1007-8.
10. Kaeser YA, Brunner F, Drewe J, et al. Severe hypotension and bradycardia associated with verapamil and clarithromycin. Am J Health Syst Pharm 1998;55:2417-8. (Pubitemid 28538076)
11. Steenbergen JA, Stauffer VL. Potential macrolide interaction with verapamil. Ann Pharmacother 1998;32:387-8.
12. Goldschmidt N, Azaz-Livshits T, Gotsman, et al. Compound cardiac toxicity of oral erythromycin and verapamil. Ann Pharmacother 2001;35:1396-9. (Pubitemid 33042075)
13. Geronimo-Pardo M, Cuartero-del-Pozo AB, Jimenez-Vizuete JM, et al. Clarithromycin-nifedipine interaction as possible cause of vasodilatory shock. Ann Pharmacother 2005;39:538-42. (Pubitemid 40270922)
14. Pai MP, Graci DM, Amsden GW. Macrolide drug interactions: an update. Ann Pharmacother 2000;34:495-513. (Pubitemid 30193784)
15. Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003;289:1652-8. (Pubitemid 37430270)
16. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006;354:1352-61.
17. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-8.
18. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-51. (Pubitemid 39025171)
19. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991;133:144-53.
20. Kirsten R, Nelson K, Kirsten D, et al. Clinical pharmacokinetics of vasodilators. Part I. Clin Pharmacokinet 1998;34:457-82. (Pubitemid 28271896)